Costs associated with treating hepatitis C could decrease substantially if the Centers for Disease Control and Prevention broadened its policy for who should receive the one-time HCV antibody test, new research has found.
A simulation performed by researchers at the University of Chicago projects that expanding the CDC’s one-time HCV testing recommendations to include patients 18 years and older could be more cost-effective, improve quality of life, and save a larger number of lives even